SCHEMBL3706307

SCHEMBL3706307

COc1ccc(CCN2C(=O)C(O)=C(C(C)=O)C2c2ccc(Br)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 1/20 0.69
RXFP1 Q9HBX9 4/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
TP53 P04637 3/20 0.60
MDM2 Q00987 2/20 0.60
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
ALDH1A1 P00352 3/20 0.59
ALOX15 P16050 2/20 0.58
POLB P06746 1/20 0.58
MAPT P10636 3/20 0.57
NPSR1 Q6W5P4 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
TDP1 Q9NUW8 2/20 0.56
LMNA P02545 1/20 0.54
KDM4E B2RXH2 2/20 0.53
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705385 0.92 USP7 (0.79) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3708643 0.91 MEN1 (0.61) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3708805 0.89 USP7 (0.66) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3706362 0.87 USP7 (0.67) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3709046 0.86 USP7 (0.78) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3716480 0.86 USP7 (0.78) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3707178 0.86 USP7 (0.78) USP7RXFP1L3MBTL1TP53MDM2
SCHEMBL3707749 0.86 USP7 (0.71) USP7RXFP1TP53MDM2MEN1
SCHEMBL3705340 0.86 MEN1 (0.78) USP7RXFP1TP53MDM2MEN1
SCHEMBL3714403 0.84 USP7 (0.69) USP7RXFP1TP53MDM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO claimed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP claimed
US-20220125760-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2022-04-28 US disclosed
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
WO-2010081783-A1 NOVEL SPECIFIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2010-07-22 WO disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed
EP-2208725-A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics S.A. (FR) 2010-07-21 EP disclosed